Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Pembrolizumab With Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer (PERICLES): A Phase II Study

NCT03971045 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT03971045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03971045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Pembrolizumab With Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer (PERICLES): A Phase II Study
Lead sponsor
European Institute of Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
May 20, 2020
Completion date
March 1, 2025
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, chest wall tumor